HDAC6 and cancer: ACY-1215 (also known as ricolinostat) is a potent and selective HDAC6 inhibitor [13, 30]; we used it in the in vivo experiment based on its antitumor effects and efficacy, both alone and in combination with various conventional treatments for cancer [31–33] and in several clinical trials [13, 30].